Price
No data yet.
Social Signal Score
Analyst Ratings
28 analystsRevenue
$200.58M+3686.69%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Timothy Herbert
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,333
- Beta
- 0.70
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 13.75
Financials
Revenue
$200.58M+3686.7%Net Income
$314.0KEBITDA
$4.08MFree Cash Flow
$14.07MEPS (diluted)
$0.01Shares Outstanding (diluted)
28.94M+132.2%Operating Expenses
$171.97MCash & Debt
$320.68MReturn of Capital
$0.00Revenue by Segment (annual)
$911.98MDividend per Share
$9.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $911.98M | $145.42M | $4.95 |
| 2024 | $802.80M | $53.51M | $1.80 |
| 2023 | $624.80M | $-21.15M | $-0.72 |
| 2022 | $407.86M | $-44.88M | $-1.60 |
| 2021 | $233.39M | $-42.04M | $-1.54 |
| 2020 | $115.38M | $-57.20M | $-2.19 |
| 2019 | $82.05M | $-33.24M | $-1.40 |
| 2018 | $50.59M | $-21.83M | $-1.50 |
| 2017 | $28.57M | $-17.51M | $-1.30 |
| 2016 | $16.43M | $-18.53M | $-1.49 |
| 2015 | $8.01M | $-21.34M | $-1.71 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $7.28
- Implied price
- $138.23
- Return from $69.97
- 14.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $68.73 — -1.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -2.0% | -3.6% | 0.5% | 4.0% | 7.1% | 9.8% |
| 3.0% | 1.3% | 5.6% | 9.3% | 12.5% | 15.4% |
| 8.0% | 6.2% | 10.7% | 14.6% | 18.0% | 21.1% |
| 13.0% | 11.1% | 15.8% | 19.9% | 23.5% | 26.7% |
| 18.0% | 16.0% | 21.0% | 25.2% | 28.9% | 32.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·18h ago·Neutral
Inspire Medical Systems, Inc. to Report Third Quarter 2026 Financial Results on November 2, 2026 MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the third quarter 2026 after the close of trading on Monday, November 2. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.
View source ↗ - Newszacks.com·12d ago·Neutral
Here's Why You Should Retain INSP Stock in Your Portfolio for Now Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.
View source ↗ - Newsgurufocus.com·17d ago·Positive
Is It Too Late to Buy Inspire Medical Systems Inc (INSP) After 5.5% Rally? GF Value Says Undervalued On September 18, 2026, Inspire Medical Systems Inc (INSP) shares rose 5.5% to a current price of $76.78. This price remains significantly below its 52-week high
View source ↗ - Newszacks.com·33d ago·Neutral
Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report? Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
View source ↗ - Newszacks.com·45d ago·Positive
INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue? Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.
View source ↗ - Newszacks.com·46d ago·Neutral
Here's Why You Should Add INSP Stock to Your Portfolio Now Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.10 per share
Typical surprise +139.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.14 vs $-0.24beat
- Mon, May 4$0.10 vs $-0.28beat
- Wed, Feb 11$1.65 vs $0.69beat
- Mon, Nov 3$0.38 vs $-0.15beat
- Mon, Aug 4$0.45 vs $0.22beat
- Mon, May 5$0.10 vs $-0.23beat
Estimates and results for INSP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INSP officers and directors.
- Bought
- $804
- Sold
- $2.0m
2 trades
12 trades
- Kelly Jason Psold
- Rondoni Johnsold
- Rondoni Johnsold
- Mccormick Shawnsold
- Rondoni Johnsold
- Mccormick Shawnsold
- Mccormick Shawnsold
- Buchholz Richardsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.